放化疗-话题@MedSci

#放化疗#

163篇内容 | 1876人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1288006, encodeId=6b8c128800641, content=<a href='/topic/show?id=4d185e31825' target=_blank style='color:#2F92EE;'>#放化疗#</a>, objectTitle=一文打尽！肿瘤免疫治疗联合放化疗、靶向治疗的机制与进展都在这了!, objectType=article, longId=739308, objectId=9d3ae3930807, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9d3ae3930807, replyNumber=0, likeNumber=51, createdTime=2022-09-16, rootId=0, userName=yzh399, userId=310e209, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9d3ae3930807, moduleTitle=一文打尽！肿瘤免疫治疗联合放化疗、靶向治疗的机制与进展都在这了!, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9d3ae3930807)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1288004, encodeId=deb312880043a, content=<a href='/topic/show?id=4d185e31825' target=_blank style='color:#2F92EE;'>#放化疗#</a>, objectTitle=Lancet Oncol：新辅助放化疗加用Galunisertib可提高局部晚期直肠癌的完全缓解率, objectType=article, longId=735465, objectId=7ce2e3546529, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7ce2e3546529, replyNumber=0, likeNumber=37, createdTime=2022-08-11, rootId=0, userName=yzh399, userId=310e209, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7ce2e3546529, moduleTitle=Lancet Oncol：新辅助放化疗加用Galunisertib可提高局部晚期直肠癌的完全缓解率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7ce2e3546529)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1288005, encodeId=d8361288005e9, content=<a href='/topic/show?id=4d185e31825' target=_blank style='color:#2F92EE;'>#放化疗#</a>, objectTitle=CAR-T之父最新Nature论文！无需放化疗，新型T细胞疗法成功治愈超半数难治型实体瘤小鼠, objectType=article, longId=731697, objectId=1fbce3169782, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1fbce3169782, replyNumber=0, likeNumber=38, createdTime=2022-07-10, rootId=0, userName=yzh399, userId=310e209, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1fbce3169782, moduleTitle=CAR-T之父最新Nature论文！无需放化疗，新型T细胞疗法成功治愈超半数难治型实体瘤小鼠, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1fbce3169782)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1288002, encodeId=202b128800251, content=<a href='/topic/show?id=4d185e31825' target=_blank style='color:#2F92EE;'>#放化疗#</a>, objectTitle=陈占红教授：中国临床肿瘤学会(CSCO）肿瘤放化疗相关中粒细胞减少症规范化管理指南（2021版）更新解读, objectType=article, longId=730239, objectId=a7f1e30239a4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a7f1e30239a4, replyNumber=0, likeNumber=38, createdTime=2022-06-24, rootId=0, userName=yzh399, userId=310e209, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a7f1e30239a4, moduleTitle=陈占红教授：中国临床肿瘤学会(CSCO）肿瘤放化疗相关中粒细胞减少症规范化管理指南（2021版）更新解读, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a7f1e30239a4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1288003, encodeId=4e4f1288003df, content=<a href='/topic/show?id=4d185e31825' target=_blank style='color:#2F92EE;'>#放化疗#</a>, objectTitle=CAR-T之父最新Nature论文：无需放化疗，合成IL-9受体增强T细胞疗法，治愈实体肿瘤, objectType=article, longId=729830, objectId=b041e298307f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b041e298307f, replyNumber=0, likeNumber=46, createdTime=2022-06-19, rootId=0, userName=yzh399, userId=310e209, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b041e298307f, moduleTitle=CAR-T之父最新Nature论文：无需放化疗，合成IL-9受体增强T细胞疗法，治愈实体肿瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b041e298307f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1288001, encodeId=354212880013a, content=<a href='/topic/show?id=4d185e31825' target=_blank style='color:#2F92EE;'>#放化疗#</a>, objectTitle=【雀巢营养100天】放化疗期间全面补充营养，保证最佳抗癌效果, objectType=article, longId=729826, objectId=ac69e298266e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ac69e298266e, replyNumber=0, likeNumber=33, createdTime=2022-06-19, rootId=0, userName=yzh399, userId=310e209, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ac69e298266e, moduleTitle=【雀巢营养100天】放化疗期间全面补充营养，保证最佳抗癌效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ac69e298266e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1288000, encodeId=8811128800002, content=<a href='/topic/show?id=4d185e31825' target=_blank style='color:#2F92EE;'>#放化疗#</a>, objectTitle=Thorac Cancer：基于PET检查分期的食管鳞癌根治术后辅助同步放化疗(ACCRT)的疗效, objectType=article, longId=728905, objectId=5bbce28905b8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5bbce28905b8, replyNumber=0, likeNumber=0, createdTime=2022-06-10, rootId=0, userName=yzh399, userId=310e209, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5bbce28905b8, moduleTitle=Thorac Cancer：基于PET检查分期的食管鳞癌根治术后辅助同步放化疗(ACCRT)的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5bbce28905b8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1287999, encodeId=2e39128e99910, content=<a href='/topic/show?id=4d185e31825' target=_blank style='color:#2F92EE;'>#放化疗#</a>, objectTitle=Eur J Cancer：Durvalumab联合放化疗治疗局限期小细胞肺癌, objectType=article, longId=726278, objectId=022de262782e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=022de262782e, replyNumber=0, likeNumber=63, createdTime=2022-05-08, rootId=0, userName=yzh399, userId=310e209, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=022de262782e, moduleTitle=Eur J Cancer：Durvalumab联合放化疗治疗局限期小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=022de262782e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1287998, encodeId=88c2128e99895, content=<a href='/topic/show?id=4d185e31825' target=_blank style='color:#2F92EE;'>#放化疗#</a>, objectTitle=Radiology：直肠癌放化疗后的MRI放射组学病理预测, objectType=article, longId=724047, objectId=744be240471b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=744be240471b, replyNumber=0, likeNumber=29, createdTime=2022-04-13, rootId=0, userName=yzh399, userId=310e209, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=744be240471b, moduleTitle=Radiology：直肠癌放化疗后的MRI放射组学病理预测, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=744be240471b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1287997, encodeId=acb5128e9979e, content=<a href='/topic/show?id=4d185e31825' target=_blank style='color:#2F92EE;'>#放化疗#</a>, objectTitle=BMC Cancer：局部晚期非小细胞肺癌（LA-NSCLC）放化疗后durvalumab治疗可改善患者的预后, objectType=article, longId=723788, objectId=3020e23788de, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3020e23788de, replyNumber=0, likeNumber=35, createdTime=2022-04-09, rootId=0, userName=yzh399, userId=310e209, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3020e23788de, moduleTitle=BMC Cancer：局部晚期非小细胞肺癌（LA-NSCLC）放化疗后durvalumab治疗可改善患者的预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3020e23788de)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1287996, encodeId=0204128e99611, content=<a href='/topic/show?id=4d185e31825' target=_blank style='color:#2F92EE;'>#放化疗#</a>, objectTitle=BMC Cancer：不可切除III期非小细胞肺癌（NSCLC）铂类放化疗进展后再给予铂类联合化疗可延长生存, objectType=article, longId=723595, objectId=19f4e2359542, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=19f4e2359542, replyNumber=0, likeNumber=30, createdTime=2022-04-07, rootId=0, userName=yzh399, userId=310e209, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=19f4e2359542, moduleTitle=BMC Cancer：不可切除III期非小细胞肺癌（NSCLC）铂类放化疗进展后再给予铂类联合化疗可延长生存, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=19f4e2359542)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1287995, encodeId=2d17128e99544, content=<a href='/topic/show?id=4d185e31825' target=_blank style='color:#2F92EE;'>#放化疗#</a>, objectTitle=BMC Cancer：比较宫颈鳞状细胞癌（SCC）和腺癌/腺鳞癌（AC/ASC)）患者根治性放化疗后的生存结果, objectType=article, longId=302023, objectId=f6e5302023a2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f6e5302023a2, replyNumber=0, likeNumber=42, createdTime=2022-04-01, rootId=0, userName=yzh399, userId=310e209, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f6e5302023a2, moduleTitle=BMC Cancer：比较宫颈鳞状细胞癌（SCC）和腺癌/腺鳞癌（AC/ASC)）患者根治性放化疗后的生存结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f6e5302023a2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1287993, encodeId=48cc128e993cb, content=<a href='/topic/show?id=4d185e31825' target=_blank style='color:#2F92EE;'>#放化疗#</a>, objectTitle=J Clin Oncol：中科院&协和 | 术前短程放疗+化疗方案或可替代局部晚期直肠癌的标准长程放化疗方案！, objectType=article, longId=300486, objectId=097730048604, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=097730048604, replyNumber=0, likeNumber=51, createdTime=2022-03-12, rootId=0, userName=yzh399, userId=310e209, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=097730048604, moduleTitle=J Clin Oncol：中科院&协和 | 术前短程放疗+化疗方案或可替代局部晚期直肠癌的标准长程放化疗方案！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=097730048604)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1287994, encodeId=b883128e99457, content=<a href='/topic/show?id=4d185e31825' target=_blank style='color:#2F92EE;'>#放化疗#</a>, objectTitle=Clin Cancer Res：陈明教授团队发现不可手术的食管鳞状细胞癌（ESCC）同步放化疗中使用放疗剂量为50Gy更合适, objectType=article, longId=300448, objectId=e70c30044809, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e70c30044809, replyNumber=0, likeNumber=55, createdTime=2022-03-12, rootId=0, userName=yzh399, userId=310e209, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e70c30044809, moduleTitle=Clin Cancer Res：陈明教授团队发现不可手术的食管鳞状细胞癌（ESCC）同步放化疗中使用放疗剂量为50Gy更合适, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e70c30044809)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1287992, encodeId=a4db128e99272, content=<a href='/topic/show?id=4d185e31825' target=_blank style='color:#2F92EE;'>#放化疗#</a>, objectTitle=BMC Cancer：多中心倾向匹配分析比较术前 vs 术后放化疗治疗局部进展胃癌患者的疗效, objectType=article, longId=299728, objectId=d846299e2851, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d846299e2851, replyNumber=0, likeNumber=26, createdTime=2022-03-01, rootId=0, userName=yzh399, userId=310e209, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d846299e2851, moduleTitle=BMC Cancer：多中心倾向匹配分析比较术前 vs 术后放化疗治疗局部进展胃癌患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d846299e2851)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1287991, encodeId=e99d128e9911d, content=<a href='/topic/show?id=4d185e31825' target=_blank style='color:#2F92EE;'>#放化疗#</a>, objectTitle=European Radiology：ADC图纹理特征在预测浸润性膀胱癌放化疗反应中的作用, objectType=article, longId=299092, objectId=6a39299092c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6a39299092c6, replyNumber=0, likeNumber=51, createdTime=2022-02-19, rootId=0, userName=yzh399, userId=310e209, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6a39299092c6, moduleTitle=European Radiology：ADC图纹理特征在预测浸润性膀胱癌放化疗反应中的作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6a39299092c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1287990, encodeId=a1bc128e99062, content=<a href='/topic/show?id=4d185e31825' target=_blank style='color:#2F92EE;'>#放化疗#</a>, objectTitle=Clin Cancer Res：局部晚期直肠癌的新治疗方案——术前放化疗联合纳武单抗巩固继以根治性手术！, objectType=article, longId=295321, objectId=eb062953218f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eb062953218f, replyNumber=0, likeNumber=41, createdTime=2022-02-10, rootId=0, userName=yzh399, userId=310e209, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eb062953218f, moduleTitle=Clin Cancer Res：局部晚期直肠癌的新治疗方案——术前放化疗联合纳武单抗巩固继以根治性手术！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eb062953218f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1287989, encodeId=3bb6128e98918, content=<a href='/topic/show?id=4d185e31825' target=_blank style='color:#2F92EE;'>#放化疗#</a>, objectTitle=Front Oncol：宫颈癌根治性子宫切除术+淋巴结清扫(RHND)+辅助放疗(RT)/同步放化疗(CCRT)后复发患者的复发模式及预后因素, objectType=article, longId=295136, objectId=26002951366f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=26002951366f, replyNumber=0, likeNumber=49, createdTime=2022-02-06, rootId=0, userName=yzh399, userId=310e209, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=26002951366f, moduleTitle=Front Oncol：宫颈癌根治性子宫切除术+淋巴结清扫(RHND)+辅助放疗(RT)/同步放化疗(CCRT)后复发患者的复发模式及预后因素, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=26002951366f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1287988, encodeId=ef8a128e98877, content=<a href='/topic/show?id=4d185e31825' target=_blank style='color:#2F92EE;'>#放化疗#</a>, objectTitle=Front Oncol：奈达铂 vs 顺铂为基础的同期放化疗治疗IIB-IVA期宫颈癌患者的疗效和安全性, objectType=article, longId=295133, objectId=e466295133ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e466295133ba, replyNumber=0, likeNumber=51, createdTime=2022-02-06, rootId=0, userName=yzh399, userId=310e209, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e466295133ba, moduleTitle=Front Oncol：奈达铂 vs 顺铂为基础的同期放化疗治疗IIB-IVA期宫颈癌患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e466295133ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1287987, encodeId=c89c128e987a7, content=<a href='/topic/show?id=4d185e31825' target=_blank style='color:#2F92EE;'>#放化疗#</a>, objectTitle=J Clin Oncol：PACIFIC研究5年生存结果提示放化疗后durvalumab（德瓦鲁单抗）持续改善III期NSCLC患者的预后，5年OS超过40%, objectType=article, longId=295111, objectId=e91429511199, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e91429511199, replyNumber=0, likeNumber=48, createdTime=2022-02-05, rootId=0, userName=yzh399, userId=310e209, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e91429511199, moduleTitle=J Clin Oncol：PACIFIC研究5年生存结果提示放化疗后durvalumab（德瓦鲁单抗）持续改善III期NSCLC患者的预后，5年OS超过40%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e91429511199)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

放化疗

2020-05-29

yzh399 (审核中...)

前往app查看评论内容

#放化疗#

一文打尽！肿瘤免疫治疗联合放化疗、靶向治疗的机制与进展都在这了!

2022-09-16

yzh399 (审核中...)

前往app查看评论内容

#放化疗#

Lancet Oncol：新辅助放化疗加用Galunisertib可提高局部晚期直肠癌的完全缓解率

2022-08-11

yzh399 (审核中...)

前往app查看评论内容

#放化疗#

CAR-T之父最新Nature论文！无需放化疗，新型T细胞疗法成功治愈超半数难治型实体瘤小鼠

2022-07-10

yzh399 (审核中...)

前往app查看评论内容

#放化疗#

陈占红教授：中国临床肿瘤学会(CSCO）肿瘤放化疗相关中粒细胞减少症规范化管理指南（2021版）更新解读

2022-06-24

yzh399 (审核中...)

前往app查看评论内容

#放化疗#

CAR-T之父最新Nature论文：无需放化疗，合成IL-9受体增强T细胞疗法，治愈实体肿瘤

2022-06-19

yzh399 (审核中...)

前往app查看评论内容

#放化疗#

【雀巢营养100天】放化疗期间全面补充营养，保证最佳抗癌效果

2022-06-19

yzh399 (审核中...)

前往app查看评论内容

#放化疗#

Thorac Cancer：基于PET检查分期的食管鳞癌根治术后辅助同步放化疗(ACCRT)的疗效

2022-06-10

yzh399 (审核中...)

前往app查看评论内容

#放化疗#

Eur J Cancer：Durvalumab联合放化疗治疗局限期小细胞肺癌

2022-05-08

yzh399 (审核中...)

前往app查看评论内容

#放化疗#

Radiology：直肠癌放化疗后的MRI放射组学病理预测

2022-04-13

yzh399 (审核中...)

前往app查看评论内容

#放化疗#

BMC Cancer：局部晚期非小细胞肺癌（LA-NSCLC）放化疗后durvalumab治疗可改善患者的预后

2022-04-09

yzh399 (审核中...)

前往app查看评论内容

#放化疗#

BMC Cancer：不可切除III期非小细胞肺癌（NSCLC）铂类放化疗进展后再给予铂类联合化疗可延长生存

2022-04-07

yzh399 (审核中...)

前往app查看评论内容

#放化疗#

BMC Cancer：比较宫颈鳞状细胞癌（SCC）和腺癌/腺鳞癌（AC/ASC)）患者根治性放化疗后的生存结果

2022-04-01

yzh399 (审核中...)

前往app查看评论内容

#放化疗#

J Clin Oncol：中科院&协和 | 术前短程放疗+化疗方案或可替代局部晚期直肠癌的标准长程放化疗方案！

2022-03-12

yzh399 (审核中...)

前往app查看评论内容

#放化疗#

Clin Cancer Res：陈明教授团队发现不可手术的食管鳞状细胞癌（ESCC）同步放化疗中使用放疗剂量为50Gy更合适

2022-03-12

yzh399 (审核中...)

前往app查看评论内容

#放化疗#

BMC Cancer：多中心倾向匹配分析比较术前 vs 术后放化疗治疗局部进展胃癌患者的疗效

2022-03-01

yzh399 (审核中...)

前往app查看评论内容

#放化疗#

European Radiology：ADC图纹理特征在预测浸润性膀胱癌放化疗反应中的作用

2022-02-19

yzh399 (审核中...)

前往app查看评论内容

#放化疗#

Clin Cancer Res：局部晚期直肠癌的新治疗方案——术前放化疗联合纳武单抗巩固继以根治性手术！

2022-02-10

yzh399 (审核中...)

前往app查看评论内容

#放化疗#

Front Oncol：宫颈癌根治性子宫切除术+淋巴结清扫(RHND)+辅助放疗(RT)/同步放化疗(CCRT)后复发患者的复发模式及预后因素

2022-02-06

yzh399 (审核中...)

前往app查看评论内容

#放化疗#

Front Oncol：奈达铂 vs 顺铂为基础的同期放化疗治疗IIB-IVA期宫颈癌患者的疗效和安全性

2022-02-06

yzh399 (审核中...)

前往app查看评论内容

#放化疗#

J Clin Oncol：PACIFIC研究5年生存结果提示放化疗后durvalumab（德瓦鲁单抗）持续改善III期NSCLC患者的预后，5年OS超过40%

2022-02-05

科室
- - 订阅+
  - 更多科室
工具
服务